Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Sectra signs contract with US cancer center for enterprise imaging

Linköping, Sweden and Shelton, CT – May 2, 2017 – International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) announces that it has signed a multi-year contract with City of Hope to install the Sectra Enterprise Image Management suite of products for display, transmission, and storage of all images throughout the healthcare system. The multi-departmental PACS and VNA solution, integrated with the Epic EMR, will enable physicians access and sharing of images and information across the entire clinical pathway.City of Hope is one of only forty-seven

Genovis expands its product portfolio and launches FabALACTICA™

Genovis is expanding its product portfolio and launching yet another unique enzyme for antibody analysis, FabALACTICA™. This enzyme is of particular interest to pharmaceutical companies that develop biological drugs in the growing immunotherapy segment. With the launch of FabALACTICA Genovis will have nine unique enzymes for antibody analysis in the product portfolio, as well as one product for labeling antibodies.Development of new biological drugs in the immunotherapy segment is undergoing strong growth. New types of therapeutic antibodies place new demands on the reagents used for

Tor Berthelius joins Beringer Finance

Tor Berthelius joins Beringer Finance as Country Manager for Sweden and will be part of the firm’s Executive Management Team.“We are extremely pleased to welcome Tor to Beringer Finance. He has considerable experience and is highly regarded in the industry. Upon joining he will be focusing on client relationships as well as expanding our Stockholm office. With a new Country Manager in place in Sweden taking over my role there, and Einar U. Johansen as Country Manager in Norway and Deputy CEO, I will now be able to fully focus on the overall development of Beringer Finance”, says Adalsteinn

Invitation to presentation of Nordic Waterproofing’s first quarter 2017 report

Nordic Waterproofing Holding A/S will publish its interim report for January–March 2017 on Tuesday, 9 May 2017 at approximately 08:00 a.m. CET. A conference call and web presentation for investors, analysts and media will be held the same day, at 10:00 a.m. CET.The CEO, Mr. Martin Ellis and the CFO, Mr. Jonas Olin, will present and comment the report as well as answer questions following the presentation. The presentation will be held in English via a telephone conference and a live webcast will be available on www.nordicwaterproofing.com 

Clavisters CEO has bought shares in the company

Clavister (NASDAQ: CLAV) today announced that Clavisters CEO Johan Öhman has  bought 15,600 shares in Clavister. Öhmans shareholding in the company amounts to 22,100 after the transaction. For more information, please contact:Johan Öhman, CEO and  president Phone:+46 727 11 73 73Mail: johan.ohman@clavister.com About Clavister Clavister is a leading supplier of software for virtual security with high performance. Its award winning system offers the highest level of protection with unmatched reliability. Clavister was founded in 1997 and offers its solutions globally through a

Camurus and Braeburn Pharmaceuticals Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038

New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients with opioid use disorderLund, Sweden and Princeton, New Jersey — 2 May 2017 — Camurus (NASDAQ STO: CAMX) and Braeburn Pharmaceuticals today announced positive top-line results from a long-term Phase 3 trial supporting the safety and efficacy of CAM2038 (weekly and monthly buprenorphine depots) in patients with moderate-to-severe opioid use disorder. “These new Phase 3 results add to the growing body of evidence supporting the use of our weekly and monthly buprenorphine

Proact to build on Amazon Web Services Cloud to transform enterprise IT service delivery

Proact is set to help enterprises across the globe leverage Amazon Web Services’ (AWS) proven technology, allowing customers to benefit from the breadth and depth of the AWS cloud service portfolio. Having invested heavily in resource training and recruitment across Europe, Proact has 60 certified engineers and architects with the expertise required to successfully integrate AWS with on-premise and hosted services.Proact has joined the AWS Channel Reseller Program which will allow organisations to combine Proact’s 20+ years of experience in delivering core IT services with Amazon Web

THQ Nordic invitation to a presentation on 16 May 2017

THQ Nordic invites you to a presentation in connection with the publishing of the first quarter results for 2017. The interim report will be published the same day, in good time before market opens.THQ Nordic invites you to a presentation in connection with the publishing of the first quarter results for 2017. The presentation, which is expected to last for a maximum one hour, will be held in English. After a presentation by CEO Lars Wingefors, you will have the opportunity to ask questions. Please dial in a few minutes before the presentation begins.Time: May 16, 10:00 (CET) Place:

NattoPharma Launches MenaQ7® Natto MK-7

Only comprehensive supplier of soy, soy-free, and nature-identical synthetic Vitamin K2OSLO, NORWAY and METUCHEN, NJ (May 2, 2017) – NattoPharma strengthens its reputation as the most comprehensive supplier, producer, and validator of Vitamin K2 as MK-7, going back to its roots by expanding its MenaQ7® line with the introduction of MenaQ7® Natto, Vitamin K2 as MK-7 derived by Bacillus subtilis fermentation and soy protein. MenaQ7® Natto provides all-trans isomers of K2 in a range of concentrations, including and up to 96% active MK-7, or 960,000 ppm concentration. “NattoPharma has driven

Kindred partners on Artificial Intelligence project together with City, University of London and BetBuddy

Kindred Group plc partners with City, University of London, and BetBuddy to explore how Artificial Intelligence (AI) can help strengthen its Anti-Money Laundering decision processes.Kindred Group (previously Unibet Group) has entered into a collaboration with the Research Centre for Machine Learning at City, University of London, and BetBuddy, the responsible gambling data analytics specialist. The research project will see Kindred support and fund a Phd to explore the use of deep learning and AI techniques to strengthen Anti-Money Laundering (AML) decision processes. “This project is

Australian clinical study published in British Journal of Dermatology presents further benefits with Nevisense

The Australian study previously presented at the World Congress of Cancers of the Skin showing that Nevisense can detect malignant melanoma three months earlier in follow-up cases and reduce the need for follow-up by nearly half, has now been published in the British Journal of Dermatology (BJD). The BJD is one the world’s leading journals within dermatology research and this is the second time that they publish an article about Nevisense and the EIS method.In the study, conducted by Dr Lilian Rocha, Associate Prof. Pascale Guitera, Prof. Scott W. Menzies et. al. at the Melanoma Institute

Bittium exhibits secure and durable Bittium Tough Mobile™ smartphone at Virve User Days event

Press release Free for publication on May 2, 2017 at 9.00am (CEST +1) Bittium exhibits secure and durable Bittium Tough Mobile™ smartphone at Virve User Days event Oulu, Finland, May 2, 2017 – Bittium exhibits its Bittium Tough Mobile™ smartphone at the Virve User Days in Vantaa, Finland, May 2-3. Virve is a nationwide administrative security TETRA radio network, which is used by Finnish authorities and other security operators for secure communications. The Virve User Days event brings together both representatives of the organizations using the network and e.g. equipment

MTG increases ownership in online games developer InnoGames

· MTG invests EUR 82.6 million to increase shareholding in InnoGames  from 21% to 51%  · InnoGames generated 25% revenue growth to EUR 130 million in 2016 with an EBITDA margin of approximately 20% and EBIT margin of approximately 16% MTG has increased its ownership in InnoGames, the developer of browser and mobile games, to 51%. MTG announced  its initial 21% investment in Hamburg-based InnoGames in October 2016. InnoGames is the creator of six

Annual Report & Accounts

SALAMANDER ENERGY plc ANNUAL REPORT AND ACCOUNTS 31 DECEMBER 2016 COMPANY NUMBER: 05934263 Strategic Report Introduction This Strategic Report has been prepared solely to provide additional information to shareholders to assess the Company’s strategies and the potential for those strategies to succeed. The Strategic Report contains certain forward-looking statements. These statements are made by the Directors in good faith based on the information available to them up to the time of their approval of this report and such statements should be treated with caution due to

Targeting renewable energy to business customers in UK

Vattenfall will start to sell renewable power for the first time to British consumers. The green power product will help business customers with high demand to reduce their carbon footprint. The drive for business-to-business customers (B2B) will start in early May.Anna Borg, Vattenfall’s new Head of Business Area Markets, said: “Vattenfall is offering a new green power product to large UK electricity users. This is the first time that Vattenfall is making a B2B supply offering in the UK. We are able to do this because of our investment in British wind capacity since 2008. Our renewable

Redemption Notice

ROYAL BANK OF CANADA Series No: 632 JPY 10,000,000,000 2.86%.Subordinated Notes due June 2037 under the U.S.$40 Billion Programme for the Issuance of Notes  ISIN - XS0305391681 NOTICE IS HEREBY GIVEN in accordance with Condition 6.03 set forth in the prospectus dated July 14, 2006 and the supplementary prospectuses dated September 8, 2006 and others respectively of the Terms and Conditions of the Notes, that Royal Bank of Canada will redeem all outstanding captioned Notes on June 26, 2017 at Par together with interest accrued to and including such date. After June 26, 2017,

Metsä Board skincare gift box wins the Luxe Pack Shanghai 2017 in green Award

Metsä Board has recently won the Luxe Pack Shanghai ’in green’ Award, in the best eco-friendly Packaging Solution category, with its skincare gift box. The skincare packaging concept is designed to promote sustainability while providing a unique user experience.Metsä Board Corporation press release 2 May 2017Metsä Board has recently won the Luxe Pack Shanghai ’in green’ Award, in the best eco-friendly Packaging Solution category, with its skincare gift box. The skincare packaging concept is designed to promote sustainability while providing a unique user experience. The concept represents

Framework agreement with Slättö no longer conditional, scope increased to a minimum of SEK 7 billion

According to previously announced press release on November 25, 2016, Magnolia Bostad entered into a framework agreement with Slättö. The agreement involves Slättö acquiring residential projects from Magnolia Bostad with a value of at least SEK 5 billion, and may gradually be increased to SEK 14 billion.The framwork agreement is no longer subject to Slättö obtaining the necessary financing and the scope of the agreement has been extended from acquisition of a minimum of SEK 5 billion to a minimum of SEK 7 billion. The possibility of expansion up to SEK 14 billion remains. The agreement

Tethys Oil AB: First quarter report - 31 March 2017

First quarter 2017 ·         Production amounted to 12,495 bopd, compared to 12,268 bopd in the fourth quarter 2016 ·         Revenue of MUSD 29.3, compared to MUSD 20.7 in the fourth quarter 2016 ·         EBITDA of MUSD 19.3, compared to MUSD 9.6 in the fourth quarter 2016 ·         Net result of MUSD 6.7, compared to MUSD 1.5 in the fourth quarter 2016 ·         Earnings per share amounted to USD 0.19 during first quarter 2017 ·         14 new wells completed on Blocks 3&4 during the first quarter 2017 ·         Two previously undrilled fault blocks on Farha South

Losses reduce subsequent risk taking among bettors – applies to many other risky decisions, too

Psychologically, loss is known to cause about twice as much pain as pleasure caused by similar gain. However, earlier studies focusing on how prior outcomes affect subsequent risk taking have reported conclusions that appear mutually contradictory. A new study carried out by the University of Eastern Finland Business School among horse race bettors shows that loss reduces subsequent risk taking, and bettors also tend to avoid loss when betting money they have already won. The findings were published in Management Science. The researchers observed the betting behaviour of more than 5,

Eklund Foundation now open for applicants within odontology

Eklund Foundation for Odontological Research and Education will distribute approximately EUR 160,000 / MSEK 1.5 to selected research projects in 2017. Applications are accepted through the online application portal at eklundfoundation.org , during the period of 1-31 May 2017. Eklund Foundation invites applicants from all fields of odontology and will particularly prioritize projects that can be related to periodontology, implantology, and cariology. Both experimental and clinical studies are welcome. The successful candidates will be announced in

NeuroVive in-licenses a genetic mitochondrial disease clinical stage project from Yungjin Pharm

Lund, Sweden and Seoul, Korea, 2 May 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced that they have entered into a global licensing agreement on Yungjin Pharm’s compound KL1333 for genetic mitochondrial disorders. The in-licensed project is about to enter Phase I clinical development.KL1333 is a drug intended for treatment of orphan genetic mitochondrial disorders. KL1333 acts through modulating the levels of NAD+ and thereby rectifying mitochondrial defects. Yungjin

Change in number of shares and votes in Gränges

The number of shares and votes in Gränges has changed as a result of the exercise of 20,000 warrants within the company’s incentive programs. At the last trading day of the month there was in total 75,175,386 shares and 75,175,386 votes in the company. For further information, please contact: Pernilla Grennfelt, SVP Communications and Investor Relations of Grängespernilla.grennfelt@granges.com, tel: +46 702 90 99 55 The information in this press release is such that Gränges must disclose pursuant to the Financial Instruments Trading Act. The information was submitted for

There are no items matching the current filter
There are no more items matching the current filter
Back to top